WO2025223455 - ANTI-PTK7/B7H3 ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/223455
Publication Date
30.10.2025
International Application No.
PCT/CN2025/090662
International Filing Date
23.04.2025
Title **
[English]
ANTI-PTK7/B7H3 ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-PTK7/B7H3 ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
LI, Peiran
GUO, Yanan
Priority Data
PCT/CN2024/089487
24.04.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4132 | |
| EPO | Filing, Examination, Granting | 53506 | |
| Japan | Filing, Examination, Granting | 3898 | |
| South Korea | Filing, Examination, Granting | 5318 | |
| USA | Filing, Examination, Granting | 24790 |
Total:
91,644
Contact Us
Abstract[English]
This disclosure relates to anti-PTK7/B7H3 antibodies, and antibody drug conjugates derived therefrom, wherein the antibodies specifically bind to at least two different antigens PTK7 and B7H3. Also disclosed are pharmaceutical compositions comprising such antibodies and antibody drug conjugates, methods of using and methods of making such antibodies and antibody drug conjugates.[French]
La présente divulgation concerne des anticorps anti-PTK7/B7H3, et des conjugués anticorps-médicament dérivés de ceux-ci, les anticorps se liant de manière spécifique à au moins deux antigènes différents PTK7 et B7H3. La divulgation concerne également des compositions pharmaceutiques comprenant de tels anticorps et des conjugués anticorps-médicament, des procédés d'utilisation et des procédés de fabrication de tels anticorps et conjugués anticorps-médicament.